Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues
Total revenue	$ 20,641	$ 4,366	$ 32,851	$ 9,220
Operating expenses
General and administrative	3,210	2,861	9,389	8,683
Research and development	1,843	1,908	7,044	5,945
Sales and marketing	141	0	141	0
Royalty expense	4,851	537	6,099	537
License fees	0	0	0	5,625
Total operating expenses	10,045	5,306	22,673	20,790
Income (loss) from operations	10,596	(940)	10,178	(11,570)
Other income (expense)
Interest income	112	20	356	31
Loss on settlement of liability	0	0	0	(50)
Gain (loss) on foreign exchange	(24)	2	(65)	(36)
Total other income (expense)	88	22	291	(55)
Income (loss) before income taxes	10,684	(918)	10,469	(11,625)
Income tax (expense) benefit	0	0	57	(33)
Net income (loss)	$ 10,684	$ (918)	$ 10,526	$ (11,658)
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ 2.64	$ (0.32)	$ 2.64	$ (4.32)
Diluted (in dollars per share)	$ 1.97	$ (0.32)	$ 1.98	$ (4.32)
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	4,048,635	2,871,042	3,985,112	2,698,532
Diluted (in shares)	5,422,345	2,871,042	5,310,157	2,698,532
Royalty and licensing revenue
Revenues
Total revenue	$ 20,494	$ 4,185	$ 30,369	$ 8,887
Treatment investment revenue
Revenues
Total revenue	0	63	644	170
Grant and contract revenue
Revenues
Total revenue	$ 147	$ 118	$ 1,838	$ 163